Gastrointestinal blood loss in haemodialysis patients during use of a low-molecular-weight heparinoid anticoagulant.
In a randomised cross-over study we assessed total blood loss in 14 dialysis patients using 59Fe as a marker for measurement in a whole-body counting system. In one period the patients received standard heparin, in the other ORG 10172, a new low-molecular-weight-heparinoid. Our results show no significant difference between the two study periods with regard to blood loss and dialyser blood retention. In some patients a delayed bleeding ('oozing') from the puncture site was noticed as a side-effect of treatment with the low-molecular-weight-heparinoid. We conclude that this heparinoid is effective as an anticoagulant in regular dialysis treatment, but it seems to have no advantage over standard heparinisation with regard to occult bleeding. This may be related to the prolonged plasma anti-Xa activity (30.8 h) of this compound compared to standard heparin in dialysis patients.
Frei
U
U
Division of Nephrology, Medical School Hannover, FRG.
Wilks
M F
MF
Boehmer
S
S
Crisp-Lindgren
N
N
Schwarzrock
R
R
Stiekema
J C
JC
Koch
K M
KM
D000328:Adult; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced* / Q000517:prevention & control; D006025:Glycosaminoglycans / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects; D006496:Heparinoids / Q000009:adverse effects*; D006497:Heparan Sulfate; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; C035838:danaparoid